EU panel recommends against nod for Puma Biotech's breast cancer drug

(Reuters) - A European Medicines Agency (EMA) panel on Friday recommended against approving Puma Biotechnology's lead breast cancer drug, an outcome the U.S drugmaker had signaled last month.